Johnson & Johnson (NYSE: JNJ) is capitalizing on its transition from a broad-based healthcare conglomerate into a market leader in innovative medicine and medical technology. The company continues to expand its portfolio through strategies such as diversification across high-growth healthcare segments and reinvestment in the business, with a focus on advanced therapeutics and state-of-the-art medical devices.
Johnson & Johnson is expected to deliver positive results for the fourth quarter, continuing the momentum seen since the beginning of the year. On average, analysts following the company forecast adjusted earnings of $2.49 per share for the quarter, higher than $2.04 per share reported in the year-ago quarter. Q4 revenues are expected to be $24.16 billion, representing a 7.3% year-over-year increase. The report is scheduled for release on Wednesday, January 21, at 6:20 am ET.
JNJ is one of the best-performing Wall Street stocks, growing more than 45% last year. A month ago, the shares set a new record, before paring a part of those gains in the following weeks. Over the years, Johnson & Johnson has maintained its commitment to returning capital to shareholders through a long-standing dividend growth streak. The company’s disciplined approach to cash flow allocation and innovation-focused investments has enabled it to consistently raise the payout for many decades.
In Q3 2025, adjusted earnings rose 16% from last year to $2.80 per share, exceeding estimates. Over the past several years, quarterly earnings have frequently beaten estimates. Unadjusted net earnings surged 91% year-over-year to $5.2 billion or $2.12 per share. At $24 billion, third-quarter reported sales were up 6.8%, while operational sales grew 5.4%. The top-line exceeded expectations. Sales rose 7% in both Innovative Medicine and MedTech, the main operating segments. Geographically, US sales rose 6% and International sales increased 8%.
“We continue to invest at industry-leading levels in our pipeline and portfolio while making disciplined decisions to exit businesses that we believe will be better able to thrive outside of Johnson & Johnson. For our Orthopaedics business, the planned separation creates new opportunities. Operating as DePuy Synthes and led by Namal Nawana, it would be the largest, most comprehensive orthopaedics company, with leading market share positions across major categories and addressing a more than $50 billion and growing market opportunity,” JNJ CEO Joaquin Duato said in the Q3 FY25 earnings call.
Buoyed by the positive Q3 outcome, the management raised its full-year sales guidance to $93.5-93.9 billion. The forecast is almost in line with analysts’ expectations. Full-year earnings guidance was reaffirmed in the range of $10.80 per share to $10.90 per share, excluding special items. Ongoing portfolio diversification has given the company a competitive advantage in an evolving industry marked by technological breakthroughs and shifting regulatory dynamics. Also, the growing demand for personalized and value-based care bodes well for the business.
The stock has been trading mostly sideways since crossing the $200 mark two months ago. That is well above its 12-month average price of $171.64. On Monday, JNJ traded higher throughout the session.
The post Johnson & Johnson heads into Q4 as a more focused healthcare leader first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
